The global Oncology Biosimilar Market is experiencing substantial growth, driven by the increasing prevalence of cancer worldwide, rising demand for cost-effective biologic therapies, and favorable regulatory frameworks supporting biosimilar approvals. Oncology biosimilars are emerging as a viable alternative to expensive biologic drugs, improving patient access to advanced cancer treatments.
The global oncology biosimilar market size was estimated at USD 8.00 billion in 2025, and is anticipated to grow from USD 9.48 billion in 2026 till USD 36.90 billion in 2034, growing at a CAGR of 18.5% from 2026–2034.
Unlock Full Report Insights and Strategic Analysis- https://straitsresearch.com/report/oncology-biosimilar-market
Key Highlights
Largest Region: Europe dominates the oncology biosimilar market due to strong regulatory support, early biosimilar adoption, and well-established healthcare systems.
Fastest Growing Region: Asia-Pacific is projected to grow at the fastest CAGR of 20.1%, driven by increasing cancer incidence, expanding healthcare infrastructure, and rising adoption of cost-effective therapies.
Largest Segment: Monoclonal antibodies hold the largest market share owing to their widespread use in targeted cancer therapies.
Fastest Growing Segment: Supportive care biosimilars are expected to witness the fastest CAGR of 19.3%, supported by increasing demand for adjunct cancer treatments.
Market Dynamics
Drivers
The oncology biosimilar market is primarily driven by the rising global burden of cancer and the increasing cost of biologic therapies. Biosimilars offer a more affordable alternative, enabling healthcare systems to manage treatment costs effectively while expanding patient access to life-saving medications. Governments and regulatory bodies across regions are encouraging biosimilar adoption through favorable policies, streamlined approval processes, and reimbursement frameworks, further accelerating market growth.
Additionally, patent expirations of several blockbuster biologic drugs are opening opportunities for biosimilar manufacturers to introduce competitive products. Advancements in biotechnology and manufacturing processes are also enhancing the quality and efficacy of biosimilars, making them a preferred choice among healthcare providers and patients.
Restraints
Despite the positive outlook, the market faces challenges such as stringent regulatory requirements and complex manufacturing processes associated with biosimilars. High development costs and the need for extensive clinical trials can limit the entry of new players. Furthermore, concerns regarding interchangeability, immunogenicity, and physician hesitation in prescribing biosimilars may hinder market growth.
Opportunities
The market presents significant opportunities with increasing investments in biosimilar research and development and growing acceptance among healthcare professionals. Emerging markets, particularly in Asia-Pacific and Latin America, offer substantial growth potential due to improving healthcare infrastructure and rising awareness about cost-effective treatment options. Strategic collaborations, partnerships, and product launches are expected to further strengthen market expansion in the coming years.
Top Market Players
Pfizer Inc.
Amgen Inc.
Novartis AG (Sandoz)
Celltrion Inc.
Teva Pharmaceutical Industries Ltd.
Biocon Limited
Dr. Reddy’s Laboratories Ltd.
Samsung Bioepis Co., Ltd.
Mylan N.V. (Viatris Inc.)
Fresenius Kabi AG
Download the Free Sample Report - https://straitsresearch.com/report/oncology-biosimilar-market/request-sample
Market Segmentation
By Drug Class:
Monoclonal Antibodies
Supportive Care Biosimilars
Others
By Indication:
Breast Cancer
Lung Cancer
Colorectal Cancer
Blood Cancer
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
About Us
Straits Research is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & market research reports.
Contact Us
Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
